SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-022919
Filing Date
2020-05-07
Accepted
2020-05-07 16:31:49
Documents
63
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-10q_20200331.htm   iXBRL 10-Q 2190888
2 EX-3.1 ntla-ex31_156.htm EX-3.1 125449
3 EX-10.1 ntla-ex101_228.htm EX-10.1 758341
4 EX-10.2 ntla-ex102_227.htm EX-10.2 95423
5 EX-31.1 ntla-ex311_6.htm EX-31.1 17022
6 EX-31.2 ntla-ex312_8.htm EX-31.2 17038
7 EX-32.1 ntla-ex321_7.htm EX-32.1 6267
  Complete submission text file 0001564590-20-022919.txt   9012562

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA ntla-20200331.xsd EX-101.SCH 40977
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20200331_cal.xml EX-101.CAL 32667
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20200331_def.xml EX-101.DEF 111100
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20200331_lab.xml EX-101.LAB 339222
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20200331_pre.xml EX-101.PRE 247257
53 EXTRACTED XBRL INSTANCE DOCUMENT ntla-10q_20200331_htm.xml XML 1775967
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 20856978
SIC: 2835 In Vitro & In Vivo Diagnostic Substances